Eloxx Pharma
Clinical‑stage biopharma focused on ribosome‑modulating therapies for rare nonsense‑mutation diseases. Lead candidate ELX‑02 is in Phase 2 trials for cystic fibrosis and nephropathic cystinosis. Active preclinical pipelines target rare kidney, skin, and oncology indications.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Manufacturing
- Industry: Pharmaceutical Manufacturing
- Employees: 18
- HQ: Watertown
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.